Clinical Observation of Magnesium Isoglycyrrhizinate in Treatment of HBV-Related Liver Cirrhosis

Objective: To evaluate the therapeutic efficacy of magnesium isoglycyrrhizinate (MIG) in treatment of HBV-related d liver cirrhosis. Methods: Sixty-five HBV-related liver cirrhosis patients were assigned to two groups by using a random number table: MIG treatment group (n = 33), and control group treated with Diammonium Glycyrrhizinate (n = 32). In all cases, the treatment course was 14 days. Alanine transaminase (ALT), aspartate aminotransferase (AST), Na + , K + , abdominal circumference, used amount of albumin were evaluated in both groups before and after treatment. Results: 1) After treatment, the reducing of ALT, AST was significant different between groups (P 0.05). 3) After treatment, abdominal circumference was significant different between groups (P 0.05). Conclusion: MIG has a good therapeutic effect in treatment of HBV-related liver cirrhosis with improvement of liver function, abdominal circumference and the patient’s life quality.